Compare AEIS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEIS | JAZZ |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.4B |
| IPO Year | 1996 | 2007 |
| Metric | AEIS | JAZZ |
|---|---|---|
| Price | $308.87 | $181.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $278.36 | $215.92 |
| AVG Volume (30 Days) | 512.1K | ★ 967.6K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ 168.53 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | $453,095,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.24 | $7.66 |
| P/E Ratio | $80.32 | ★ N/A |
| Revenue Growth | ★ 38.39 | N/A |
| 52 Week Low | $75.01 | $95.49 |
| 52 Week High | $350.00 | $198.00 |
| Indicator | AEIS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 53.45 |
| Support Level | $288.91 | $176.67 |
| Resistance Level | $350.00 | $182.99 |
| Average True Range (ATR) | 15.56 | 6.47 |
| MACD | -4.94 | -1.01 |
| Stochastic Oscillator | 32.93 | 22.26 |
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.